17/12/19 -"We have hiked our estimates on account of: 1. Faster than expected growth in the acquired Osiris business, which will result in a material uplift in the performance of the wound care business 2. ..."
Pages
64
Language
English
Published on
17/12/19
You may also be interested by these reports :
30/12/25
Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong ...
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...
09/12/25
In addition to our estimates being revised lower, we have applied a 10% discount to peer-based valuation metrics to reflect the delayed recovery in ...